Cinclus Pharma: All patients have completed treatment in Phase III study - Redeye

Redeye briefly comments on Cinclus Pharma’s announcement that the last patient in the phase III HEEALING1 study with lead candidate linaprazan glurate has completed the full eight-week treatment period.

Länk till analysen i sin helhet: https://www.redeye.se/research/1184041/cinclus-pharma-all-patients-have-completed-treatment-in-phase-iii-study?utm_source=finwire&utm_medium=RSS